The authors report a case where a quantitative assessment of the apparent diffusion coefficient (ADC) of liver metastasis in a patient undergoing chemotherapy has shown to be an effective early marker for predicting therapeutic response, anticipating changes in tumor size. A lesion with lower initial ADC value and early increase in such value in the course of the treatment tends to present a better therapeutic response. Keywords: Magnetic resonance imaging; Diffusion; Liver metastases; Breast cancer; Chemotherapy; Therapy monitoring.
The assessment of cancer and its metastases by means of functional imaging techniques may lead to a more reliable diagnosis and early knowledge of the treatment efficacy. Diffusion-weighted magnetic resonance imaging (MRI) represents a promising imaging tool for tissue characterization, prediction and evaluation of therapeutic response in oncology (12) . In cases of liver disease, diffusion-weighted imaging presents higher sensitivity in the detection of lesions as compared with T2-weighted sequences (13) . Diffusion-weighted MRI is a noninvasive imaging technique which measures the water mobility within the tissues (1, 14) . The quantitative diffusion analysis is performed by means of the apparent diffusion coefficient (ADC), which is inversely proportional to the cellularity (14) . High ADC values correspond to greater freedom of motion of water molecules, for example, when some intact cell structures, such as membranes, are present. Processes such as cell apoptosis and proliferation influence the cell density and therefore the ADC value (12) . Diffusion is a cell marker. Malignant lesions, such as liver metastases, frequently demonstrate low ADC values, except in cases of treated lesions or necrosis (15) . Low
INTRODUCTION
Breast cancer is the most common malignant tumor in women (1) . The Brazilian radiological literature has recently been very preoccupied with the role played by imaging methods in the improvement of the diagnosis of breast cancer (2-11) . Most patients with metastatic breast cancer will receive numerous antitumor therapies in an attempt to minimize symptoms and prolong life. The oncology objective is to individualize the patient care to improve the therapeutic responses (1) . Thus, the availability of a tool for early monitoring of the therapeutic response is desirable, avoiding the treatment toxicity and unnecessary expenses.
ADC values (indicative of lesions with high cellularity) measured before the beginning of the treatment correspond to a subsequent good therapeutic response, indicating a greater decrease in tumor volume after chemotherapy (16) . Non significant changes in ADC were observed in lesions not responding to chemotherapy or in healthy liver parenchyma (16) . Pretreatment ADC values in tumors submitted to chemotherapy seem to be useful to evaluate the therapeutic response of liver metastasis (17) . 
CASE REPORT

DISCUSSION
Patients with history of breast cancer are susceptible to develop liver metastasis in the course of the disease. Chemotherapy plays a relevant role in management and eradication of such lesions. However, the therapeutic response can hardly be predicted (1) . With the use of diffusionweighted MRI, it can be observed that, in most tumors, an increase in the ADC value after the treatment initiation occurs in response to the therapeutics, reflecting the cell death induced by the treatment . In the presently described case, chemotherapy was initiated as soon as it was evidenced that the liver lesions were suggestive of involvement secondary to the base disease, and after follow-up with diffusionweighted MRI. The lesions detected at the first follow-up study demonstrated early, significant increase in ADC, within about one month of treatment (seven-cycle chemotherapy).
Tumors are highly heterogeneous in terms of morphology, physiology (blood flow and vascular permeability) and genetic expression levels. Such variations in the tumor tissue may significantly regulate the therapeutic interventions efficacy. Because of the excellent imaging resolution and quantification provided by diffusionweighted MRI, it can be utilized as guidance in the early phases of the treatment, with basis on the different regions where there is response or resistance to the therapy. For example, in an individual submitted to chemotherapy for a primitive neuroectodermal tumor, the mean diffusion values for the anterior and posterior regions of the tumor were measured in a determined period. The anterior region demonstrated a significant increase in the diffusion values during the first three weeks of treatment, as compared with the posterior region of the tumor, indicating that the treatment was less effective in this region. In fact, 14 weeks later, the tumor had progressed in the posterior region, revealing that such region was probably resistant to the chemotherapy. The use of diffusionweighted in the follow-up of regional changes in tumors like the one described in the present case is potentially useful to guide the treatment. It is expected that such method can provide an early evidence of the therapeutic efficacy, before the treatment is completed, offering an additional parameter to evaluate the response for continuing or changing the treatment in case of ineffectiveness (20) . Because of molecular and cell changes induced by the treatment which precede macroscopic changes such as, for example, in tumor size, diffusion-weighted MRI can be utilized to detect early changes in the lesion structure, thus allowing the use of such imaging marker as an indicator of early response in oncology. Additionally, the diffusion-weighted MRI technique allows a noninvasive evaluation of response on anatomical regions or histological subtypes, or after new molecular therapies which have not been accessible with conventional radiological methods (14) .
CONCLUSION
Changes in ADC may occur in lesions submitted to chemotherapy, before changes in the lesion size can be perceived, thus allowing that therapeutic decisions can be made in advance. Diffusion-weighted MRI has shown to be a promising tool in the prediction of the tumor response and follow-up of oncological patients undergoing chemotherapy.
